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ABSTRACT
Zyflamend, a polyphenol herbal supplement, includes numerous different
extracts. This botanical complex has been used as a natural anti-inflammatory due
to its impact on COX-2. More recently, research has exhibited its potential as an
anti-cancer agent. Currently, the effects of Zyflamend in non-cancer cells,
specifically adipocytes, has yet to be explored. Due to Zyflamend’s ability to
promote activation of AMPK, it may prove relevant to study the potential
interactions with cells treated with Zyflamend during differentiation, a metabolically
involved process. This study sought to determine the impact of Zyflamend on noncancer cells such as 3T3-L1 adipocytes during differentiation and identify the
mechanisms involved. Zyflamend was shown to effectively and significantly
attenuate adipogenesis by downregulating markers of lipogenesis, decreasing
glucose uptake by downregulating GLUT4, and upregulating hormone-sensitive
lipases. These effects halted differentiation of 3T3-L1 cells and altered their
metabolic dynamic. As evidenced in previous research, Zyflamend was found to
increase phosphorylation AMPK, affecting fatty acid metabolism. Furthermore, an
upregulation of PKA-regulated lipolysis through pHSLS660 was unexpectedly
observed. In addition, Zyflamend drastically increased activity of JNK. Through
investigation of these effects, partial rescue of adipogenesis was observed through
treatments with PKA inhibitor H89 and AMPK inhibitor BML275; however, the
presence of JNK inhibitor SP600125 showed the strongest rescue over the effects
of Zyflamend on differentiation. These results suggest Zyflamend’s effect on
iv

attenuating adipogenesis may be modulated in part by upregulation of JNK and
PKA. The ability of Zyflamend to attenuate the adipogenesis process suggest a
potential to target cell differentiation mechanisms relevant to energy metabolism.
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CHAPTER ONE
INTRODUCTION
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1. Obesity
Obesity affects over two thirds of the nation and is associated with
increased risk of a multitude of comorbidities including cardiovascular disease,
diabetes, and cancer. Understanding how adipose tissue develops and matures
is essential to the development of dynamic intervention strategies to counter its
prevalence. Previous literature has comprehensively explored adipose tissue’s
ability to store excess energy and regulate metabolic requirements. Addressing
the mechanisms associated with adipocyte differentiation has made
adipogenesis a viable target for a variety of therapeutic approaches. While
current pharmaceuticals tend to combat symptoms of obesity, the safety of these
medications is often disputed. On the other hand, a growing body of evidence
suggests that a new era of nutraceuticals may provide health specialists new
means of treating the disease through the use of phytochemicals.

Overview
Over the last few decades, the prominent trend in increasing body weight
has sparked concern for a worldwide obesity epidemic. Obesity has been
correlated with the prevalence of many other diseases such as cancer, metabolic
disorders, and other illnesses1. Epidemiological studies during this time have
sought to identify the relationship obesity may play in these occurrences2. This
has resulted in an international scientific movement exploring causes and
symptoms of obesity and investigating its pathogenesis.
2

“Obesity” is a term coined through the use of the body mass index
screening tool with a designated value of 30.0 or greater. Although not a clinical
diagnosis, many health professionals continue to use BMI as a means of
determining weight status and health risk. It is assessed by calculating weight in
relation to height, but can be further supported through other direct
measurements determining overall fat density. These methods may range
through the use of skin calipers, measuring hydration levels, fatness density via
densiometers, or through dual energy x-ray absorptiometry (DXA scan).
In the last forty years, researchers have identified a distinct pathology of
obesity increasing the interest in potential therapeutic interventions. Improving
activity levels and decreasing dietary intake have shown the most promising
evidence in reducing symptoms of obesity, but as cases become more extreme,
other more severe methods have been considered. These cases have ranged
from surgical procedures to reduce stomach size, to pharmaceutical alternatives
that mediate symptoms or alter nutrient absorption. Instead, efforts to find
alternative effective therapeutic interventions that rely less on pharmaceuticals
may counter disease-based physiological changes.
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2. Obesity and Health
Epidemiology and Current Statistics
The National Health and Nutrition Examination Survey, through the NCHS,
has conducted a stratified, multistage probability sample of the civilian
noninstitutionalized population of the United States1. This data focused on the
prevalence of overweight, obesity, and severe obesity among adults age 20 and
over between the years of 1960-2016. According to their findings, 39.8% of
adults in the United States are currently obese, with 70.1% as overweight or
obese. Variances in BMI were accounted to include differences among genders,
ethnicity, demographic, and age. Designated a chronic medical disease state,
obesity is responsible for a number of comorbidities including cardiovascular
disease, diabetes, kidney disease, cancer, as well as many other disease related
deaths and continues to be a spreading epidemic2, 3.

Etiology and Pathophysiology
The development of obesity can result from behavioral, social, cultural,
genetic, and physiological factors4. This exposes the pathology of obesity to be
of complex, multidimensional origins. Occurrence of obesity is dependent on an
imbalance between dietary intake and energy expenditure. As intake supersedes
energy requirements, physiological mechanisms occur to store excess energy in
case energy needs shift (such as during starvation or activity). The development
4

of adipose tissue is the body’s means of providing energy storage sites in cells
called adipocytes. Among many other functions, adipocytes are responsible for
excess energy storage in the form of triglycerides and have the ability to increase
their volume up to several thousandfold to accommodate excess lipid storage5.
Many institutes, such as The World Health Organization Consultation on
Obesity, have focused predominantly on behavioral and environmental factors
responsible for dramatic increases in dietary intake4. An increase in sedentary
lifestyles coupled with excessive energy intake has been suggested to be
primarily responsible for changes in adiposity6-8. Changes in dietary patterns
contributing to preferences towards sugar-sweetened beverages, high fat, and
high nutrient dense foods appear to be the culprit in many studies9, 10. Economic
changes in fast-food and convenience food institutions providing budget-friendly,
high calorie foods have also contributed to the ease of access of obesitypromoting foods10. Despite substantial evidence suggesting environmental and
behavioral influences increase risk of obesity, additional confounding evidence
has been unable to explain every occurrence. This has supported the paradigm
shift of research efforts to begin investigating additional genetic, epigenetic, and
physiologic influences.
As adipose tissue increases, changes in metabolic function and health
have been observed in a multitude of studies2. Obesity is a major contributor to
metabolic dysfunction, resulting in changes to glucose intolerance and insulin
resistance11. In addition to adipocytes’ ability to store excess energy, adipose
5

tissue exhibits endocrine system functions by regulating fat metabolism through
secreted hormones and growth factors12. In cases of obesity, many studies have
suggested that dysregulation of hormones may contribute to symptoms that
perpetuate the disease and increase the risk of comorbidities13. Also known to
influence organ dysfunction, obesity has been shown to increase prevalence of
cardiac, liver, intestinal, pulmonary, endocrine and reproductive diseases13.
In some cases, as increases in adipose deposits occur the body reaches a
degree of capacity with lipid storage and resorts to adipose deposits in other
sites. This contributes to diseases such as non-alcoholic fatty liver disease (or
NAFLD) and other diseases where adipose deposits affect organ health14, 15.
Exhausted storage of triglycerides in adipocytes prevents adequate clearance of
circulating fatty acid levels resulting in hypertriglyceridemia and lipotoxicity13. The
production of inflammatory adipokines, or cytokines secreted by adipocytes, is
associated with the development of hypertension and changes in endocrine
secretion. Changes in inflammatory response have displayed coordinated direct
effects on immune dysfunction, heightening risks of cancer, including
hepatocellular, esophageal, and colon cancers15, 16. The cumulative and
accelerating effects of obesity have been profound on modern society and its
resolution of equally profound significance in improving health worldwide.
Biology of Adipose Tissue
In mammals, adipose tissue sites are formed and support excess energy
stores. White adipose tissue (WAT) and brown adipose tissue (BAT) can function
6

in similar ways: through storage of energy. However, they vary in phenotype,
primary function, and metabolic capacity. The principal role of WAT is as an
endocrine organ and energy storage site; regulating glucose uptake and
lipogenesis/lipolysis pathways. WAT’s ability to mobilize lipid deposits makes it
instrumental in a body system’s metabolic capacity. BAT varies in phenotype by
exhibiting multiple, smaller lipid droplets and increased numbers of mitochondria
with uncoupling protein-1 (UCP-1), facilitating heat production by bypassing the
respiratory chain to ATP synthetase16. The unique metabolic variances between
the two types has developed a strong interest in the development and regulation
of BAT due to its potential role in protection against obesity and other metabolic
disorders.
Brown and white adipocytes share the ability to expand substantially to
encapsulate large levels of lipids. The ability of mature adipocytes to swell
previously lead scientists to believe adipose tissue consisted exclusively of
adipocytes, however recent studies have shown that adipose tissue has a large
variability of cell type. Many different types of cells can form vascular stroma
cells, including pre-adipocytes and macrophages; accounting for 10% of WAT in
obese individuals17. Other cell types include stem cells, endothelial cells, and the
presence of neutrophils and lymphocytes. Adipose depots may additionally be
influenced by the level of inflammation produced from surrounding tissue,
causing each depot site to be unique in its makeup17.
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As the state of obesity progresses, adipose tissue undergoes various
cellular and structural modelling processes, such as tissue expansion by
adipocyte hypertrophy and hyperplasia18. Adipocytes can facilitate rapid
remodeling of the extracellular matrix to allow for tissue expansion improving
their level of plasticity to retain normal lipid storage19. Research has suggested
that appropriate WAT plasticity seems to act as a safeguard against metabolic
disorders20. Improving the plasticity of adipose tissue by increasing its anabolic
function has been a strong focus for therapeutic strategies. Other focuses have
investigated “browning”, or the conversion of white adipocytes to acquire more
phenotypic similarities to brown adipose tissue. This term describes the process
of increasing the thermogenesis function through recruitment of pre-existing BAT
activation or BAT differentiation factors21, 22

White Adipose Tissue
Development Origin of WAT
White adipose tissue (WAT) coordinates systemic metabolism through
energy storage and hormone regulation23. The developmental pathway of WAT is
a dynamic force that responds to homeostatic and external cues. Changes to this
process have been associated with the development of various disease states
resulting in hyperglycemia, hyperlipidemia, hypertension, diabetes, liver disease,
increased carcinogenesis, cardiovascular disease, and obesity24.
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The formation of adipose tissue begins in utero during the peripartum
period and continues throughout life25. In humans, the first “fat lobules” seem to
be formed at the head level, around the 14–24th week of gestation26. These
lobules then progressively appear in the trunk, then in the limbs, and by 28
weeks they can be detected in all presumptive visceral and subcutaneous WAT
locations. In rodents, WAT cannot be macroscopically detected during
embryogenesis and develops mainly after birth, first in the perigonadal and
subcutaneous depots, and only later in the omental depot27. In humans,
adipocytes are postulated to arise from mesodermal stem cells typical to the
adipose tissue stroma28. These adipose mesenchymal stem cells form preadipocytes. This initial phase known as “determination” is characterized by their
loss of ability to differentiate into other mesenchymal paths; committing to their
adipocytic lineage28. Terminal differentiation is then initiated, whereby preadipocytes take on adipocyte characteristics and differentiate into mature white
adipocytes through cascade events triggered by IGF-1, macrophage colony
stimulating factor, fatty acids, prostaglandins, and glucocorticoids29. These
positive stimulators work to activate transcription factors PPARγ and
CCAAT/enhancer binding protein (C/EBP) known to promote adipogenesis30.
Although typically the cellular content of adipose tissue is made of
adipocytes, stromal vasculature fraction of fibroblasts, endothelial cells,
macrophages and pre-adipocytes, WAT in humans expresses a unique depotspecific genetic profile depending on site or origination31. This has been well
9

evidenced in human and mice studies, suggesting a varying developmental
program adding to the unique heterogeneity of the tissue32. Depot-specific
adipocyte compositions account for the gene and developmental differences
found in subcutaneous (SAT) and visceral (VAT) WAT locations. The function of
VAT is genetically unique to account for different metabolic functions and activity
in comparison to SAT and even peripheral adipose tissue. VAT is comprised of
intraperitoneal (including omental, mesenteric, and umbilical), extraperitoneal
(peripancreatic and perirenal), and intrapelvic (gonadal, urogenital) adipose
tissue. These anatomic locations are associated with increased metabolic
activity, compared to subcutaneous (truncal, mammary, gluteofemoral) adipose
tissue depots73.
In addition, a preference for depot sites has been reported between
genders; women tend to accumulate fat around peripheral and subcutaneous
depots resulting in a “gynoid” distribution. Conversely, men have increased
visceral depot deposits representing an “android” distribution33. Although women
typically present a higher fat mass by roughly 10% in comparison to men, the
distribution of the fat mass seems to alleviate the influence of the risk in
associated diseases34. Sex hormones are responsible in modulating this
distribution with estrogen levels supportive of fat mass accumulation in the
femoral-gluteal subcutaneous depots. Additionally, stress hormones such as
glucocorticoids have been found to induce fat accumulation in neck and upper
back depots over prolonged exposure35. Several reviews have been written
10

linking glucocorticoids to Cushing’s syndrome, impaired peripheral glucose
uptake, dysregulated blood pressure and obesity34, 36.
Distinctive consequences are associated with each adiposity distribution
between depots. It is important to note that there is clinical evidence supporting
that increased visceral adipose tissue depots relate to increased risk factors of
type 2 diabetes, hypertension, and lipidemia32. This may account for the
increased prevalence of men exhibiting symptoms of metabolic and
cardiovascular disease in comparison to women of similar age. Alternatively,
increased SAT accumulation has been shown to intensify coronary heart disease
(CHD) and peripheral vascular disease risk37.
Varying levels of bioactive molecules and their influence on enzymatic
processes associated with fat metabolism have also been reported between SAT
and VAT. Intrinsic differences in various gene expression levels, such as
increased expression of Shox2, En1, HoxC9 and Gpc4 have been found in
subcutaneous depots31. In addition, visceral depots expressed higher
transcription of genes Sfrp2, Nr2f1, Thbd, HoxA5, HoxC8 and Tbx1531. These
differences are not concentrated to variances solely between subcutaneous and
visceral locations, but seem to continue across other anatomical locations,
although the relationship between VAT and SAT has been heavily investigated
due to their varying associations with metabolic disease.
Further distinctions in characteristics include the preference of WAT
depots to adjust growth type to favor adipocyte cell number (hyperplasia) over
11

cell size (hypertrophy) and vice versa. As suggested, type of stem/progenitor
cells expressed in each depot can account for the variances between
proliferative and adipogenic properties25. Expansion over proliferation can have
impressive connotations depending on the depot of origination. Adipocyte
hypertrophy has been shown to have a lesser impact on an altered lipid profile in
women over adipocyte hyperplasia38. Although these cases may be specific to
each depot, it has been suggested that a 10% increase in omental adipocytes
(as part of VAT type depots) increases hyperlipidemia risk 4-fold from baseline,
whereas enlarged subcutaneous adipocytes failed to significantly alter
hyperlipidemia risk38.
To influence this balance between hypertrophy and hyperplasia, growth
factors in adipocytes are dependent on a strong cross-talk relationship between
adipose cells to support energy storage demands. Clonal pre-adipocytes, a
subtype typical of subcutaneous WAT depots, undergo extensive lipid
accumulation, and express strong replicative and adipogenic characteristics
resistant to TNF-alpha induced apoptosis39. This tissue seems to express lowdensity lipoprotein-related protein (LRP)-5 in the WNT signaling cascade as a
major regulator for its distribution40. However, visceral depots have markedly
weaker characteristics in both inheritable and cell-autonomous manners despite
confirmation of same pre-adipocyte lineage41. These indicators contribute to the
extent of hypertrophy/hyperplasia represented in the anatomic depot.
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Genetic and Epigenetic Control of WAT
As discussed, WAT’s difference in phenotype from BAT originates with its
own distinct genotype. The differentiation of white adipocytes requires a myriad
of transcription factors elegantly working together coordinating processes that
often work with each other. When the conditions are ripe for adipogenesis, the
sequence is activated through the transcription factor activating protein-1 (AP-1).
AP-1 triggers the induction of PPARγ; which is essential for trans-differentiation
of mesenchymal stem cells, or MSC’s, to initiate pro-adipogenic transcription
factors. To shift toward mature adipocyte differentiation, other transcription
factors are employed to stimulate, activate, and regulate the process toward
growth and proliferation.

AP-1
AP-1 consists of a family of transcription factors including v-Jun, JunB,
JunD, c-Jun, v-Fos, Fos B, c-Fos, ATF2/3, B-ATF, and Fra1/242. The role of
these transcription factors is to employ direct interaction with DNA to regulate
gene expression involved in differentiation and proliferation. Evidence supporting
the role of AP-1 members and their role in adipocyte differentiation originated
from research investigating the effects of transgenic mice generated to interrupt
DNA binding with C/EBP and Jun family transcription factors42. This produced
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mice lacking white adipose tissue and elucidated the necessity of AP-1
transcription factors in adipogenesis43.

WNT
The wingless-type MMTV integration site family members, or WNT family,
is responsible for the regulation of adipogenesis and is comprised of 19 secreted
glycoproteins that mediate adult tissue homeostasis through multiple pathways44.
These proteins act locally on autocrine and paracrine growth factors and mediate
cell to cell communication essential for adipocyte maintenance and remodeling
by repressing adipogenesis when needed45. In experiments disrupting the
canonical WNT signaling pathway, preventing the convergence of receptors
Frizzled(Fzd)/LRP-5/6 in stimulating the transcriptional factor ß-Catenin pathway,
spontaneous adipogenesis occurs, suggesting a strong correlation with WNTs in
restraining pre-adipocyte differentiation by blocking induction of PPARγ and
CEBPA46, 47. Adipocyte fate determination and stem/progenitor cell self-renewal
is associated with this pathway, though conversely, a noncanonical WNT
pathway can also occur47. The ß-catenin independent noncanonical pathway is
associated more with regulating crucial events associated with embryonic
development. It differs from its sister pathway by circumventing its reliance on ßcatenin and triggering other receptors outside of Fzd; however, little is known
about how the non-canonical receptor is activated47.
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KLF
Other transcription factor families interact with zinc-finger DNA domains,
such as the Kruppel-like family. KLF’s have been implicated in cell development,
differentiation, and proliferation and display critical roles of gene activation and
suppression48. To date, 17 members have been identified; in adipogenesis,
however, KLFs 4, 5, 6, and 15 have proven to be stimulators of adipogenesis49.
Several studies have identified these factors to be highly expressed in WAT preadipocytes during differentiation and may also contribute to lipid accumulation
and insulin sensitivity49-51.

C/EBP
Additionally, consider the role of “leucine zipper” transcription factors in
the family of CCAAT/enhancer-binding proteins (C/EBPs). Each of the six
isoforms of C/EBPs serve as an interaction point between sequence-specific
DNA and bZIP domains connecting other transcription factor families52. Ample
research has supported the observation that C/EBPs promote adipogenesis. In
vivo studies have compared the relationship of the various isoforms and their role
in adipose tissue development. In general, C/EBP deficient mice are marked by
low levels of lipid accumulation and defective adipocyte proliferation53, 54.

15

SREBP-1
During an investigatory study by the Speigelman group examining basic
helix-loop-helix DNA binding proteins, a novel member of these bHLH-leuzine
zipper transcriptions factors was identified55. Originally termed “adipocyte
determination and differentiation factor-1” or ADD-1 in mice studies, the human
homolog was renamed as the sterol response element-binding protein-1, or
SREBP-156. SREBP’s contain three isoforms (SREBP-1a, -1c, and -2) that
function as critical factors of adipocyte development that binds to the sterol
response element in the promoter region of low-density lipoproteins receptors57.
In vitro studies have shown that point-mutations inhibiting the expression of ADD1/SREBP-1 repressed adipocyte marker genes and prevented differentiation58.
Efforts to mirror results in in vivo studies have been less consistent; transgenic
mice with SREBP-1 knockout expression developed adipose tissue with limited
inhibition of adipocyte markers lipoprotein lipase and adipocyte lipid binding
protein59. Despite other studies conferring that SREBP-1 may not be required for
adipogenesis, further analysis is necessary to determine its full role in adipose
tissue proliferation and development60.
Epigenetic modifications through DNA methylation and histone
modifications can also result in influential changes to regulating gene
expressions and shifts in phenotypes influencing states of disease. Gene
repression has historically been associated with epigenetic changes in the
context of CG dinucleotides (CpG islands) through changes in body mass index,
16

physical activity, and type 2 diabetes61. These changes have been associated
with altered cellular composition of WAT and not necessarily linked to true
genetic changes to specific cell types62. Typical environmental factors known to
influence the epigenetics of WAT include decreased/increased physical activity,
increased/decreased dietary intake, and storage. The epigenetic influence of
obesity is an expanding topic that may yield insight into disease development
and prevention. In a study comparing post-obese and never-obese women, a
series of genes were mapped and compared exposing 8504 demethylation sites.
Nearly 30% of the genes linked to adipogenesis displayed genetic modifications
due to DNA methylation63. Other pathways shown to be over-represented
included pathways linked to cell differentiation (i.e. WNT signaling), apoptosis,
and autophagy. In this particular study, researchers elucidated 18 adipogenesis
genes differentially expressed due to increased body fat: IGF1, NCOR2, RARA,
MEF2D, SREBF1, NRIP1, LIFR, EBF1, GDF10, KLF5, AHR and PLIN263. Other
genes linked to lipid turnover such as ABCG1, AGPAT4, and ACAD9 were
shown to have differential gene expression, suggesting common epigenetic
changes resulted in increases of lipid accumulation and lipid synthesis63. Other
variances were noted in genes specific to obesity, such as the MRAP2 and
RCAN2 gene. Interestingly, some epigenetic changes can be reversed upon
weight loss, although adipocyte cell numbers are not affected. In conclusion,
epigenetic marks and chromatin-modifying proteins increase adipogenesis and
control metabolism through maintenance of mature adipocytes64.
17

WAT Functions
The traditional role of adipose tissue is well understood; the storage of
energy and the release of fatty acids when fuel is required. The extent of the role
WAT plays in metabolism has proven to be more complex. An evolving concept
of adipose tissue as an endocrine organ has continued to gain footing, expanding
on previous interpretations. This includes adipocytes’ ability to sense, manage,
and send signals to adjust energy equilibrium within the body. This metabolically
active tissue regulates through endocrine, paracrine, and autocrine signals that
extends to other organs involved in metabolism regulation (i.e. brain, liver,
muscles, and pancreas)65.
WAT’s contributes to lipid metabolism through opposing processes of
lipogenesis and lipolysis. Lipogenesis is the synthesis of esterified fatty acids to
form triglycerides from energy sources consumed in the diet. In humans, the liver
is predominantly responsible for the process in response to a postprandial state
and the process is inhibited in fasting conditions. Once released, these fatty
acids are entered into circulation through chylomicrons in their non-esterified
form and become reliant on adipose tissue uptake for re-esterification and
eventual lipid storage66. Insulin released during feeding stimulates enzymes
involved in fatty acid biosynthesis and uptake, including sterol regulating
element-binding protein (SREBP). Once in the cell, transcription factors
regulating lipolysis work to hydrolyze the triglycerides in preparation for storage66.
18

Perilipin A acts to surround the triglycerides, preventing access of lipases to
degrade the lipids and ß-adrenergic stimulation of adipocytes induces
downstream effectors to move and increase lipid droplet accumulation in white
adipocytes. Lipogenesis is required for proper energy packaging and storage,
allowing for its counterpart, lipolysis, to have the proper components available for
degradation. Dysregulation of lipogenesis has been linked to obesity, type 2
diabetes, and cardiovascular disease. Thus, proper regulation is necessary for
signaling factors to appropriately balance the flux of lipogenesis and lipolysis
pathways.
At times, when mammals experience an increased need of energy
requirements, adipose tissue responds by appropriating stored fatty acids
through lipolysis. The innervation of white adipose tissue from the sympathetic
nervous system works to activate lipolysis through ß-adrenergic factors (i.e.
epinephrine) to stimulate adipose triglyceride lipase (ATGL), hormone sensitive
lipase (HSL), and perilipin A phosphorylation67. Epinephrine stimulates cyclicAMP-mediated activation of protein kinase A (PKA). PKA phosphorylates ATGL
as the first responder to hydrolyze triglycerides into diglycerides and fatty acids68.
Activation of accessory proteins and HSL further hydrolyzes to produce
monoglycerides and fatty acids. Monoglyceride lipase ends the chain by
generating glycerol and a third fatty acid69. These key contributors of stored
triacylglycerol breakdown produce non-esterified fatty acids to be delegated to
peripheral tissues as energy to be oxidized70.
19

Studies have shown that lipolytic enzymes may be directly inhibited by the
presence of insulin, suggesting that insulin directly mediates nutritional
regulation. As with all metabolic processes, relative balance is required to
prevent dysregulation. Understanding the mechanisms and influences of all
metabolic systems and their harmonizing relationships with WAT is essential to
understanding the development and pathophysiology of obesity, diabetes, and
other metabolic disorders.
In 1994, Jeffrey Friedman and Douglas Coleman discovered leptin, the
adipocyte cell-produced hormone that signals to the brain the energy status of
peripheral tissues71. This discovery seemed to illuminate researchers to the
potential of a physiological feedback loop controlling energy homeostasis and
improve the understanding of the genetic and neuroendocrinological potential of
adipose tissue. As these investigations continued, the ability of adipocytes to
influence physiological processes through the secretion of adipokines became
evident. Adipokines, comprised of hormones, cytokines, and other proteins with
specific biological function, are unique to adipocytes and are involved in energy
homeostasis, extracellular matrix dissolution and reformation, angiogenesis,
steroid metabolism, immune response, and hemostasis72, 73. As researchers
have continued to elucidate the potential of adipokines, adipose tissue has
expanded its role from excess energy storage to a fundamental participant in
energy metabolism control.

20

In recent years, the list of adipokines has expanded rapidly to include
resistin, adiponectin, apelin, visfatin, retinol-binding protein-4 (RBP-4), serpin,
lipcalin-2, vaspin, omentin, in addition to inflammatory cytokines TNF-alpha,
interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). In order to
understand some of these functions, a few of these adipokines should be
discussed.
Certain adipokines have developed a role in modulating glucose
intolerance, such as resistin and RBP-4. Resistin acts to induce insulin
resistance in insulin sensitive tissues such as muscle and adipose tissue and
may be related to fasting adaptation74. In animal studies, RBP-4 has also been
shown to decrease insulin sensitivity and seems to be highly expressed in insulin
resistant obese individuals75. Conversely, adiponectin enhances insulin
sensitivity and decreases influx of non-esterified fatty acids, increasing oxidation
in the liver and muscle76. Of interest is adiponectin’s ability to increase
uncoupling protein 2 (UCP-2) and acyl coenzyme oxidase expression in muscle
and improving PPARγ expression in adipose tissue76. These genes improve lipid
catabolism and decrease lipid storage, improving metabolic parameters. Apelin is
also known to influence obesity by improving cardiovascular function through
increasing cardiac contractility and lowering blood pressure77. Interestingly, the
distribution and activation of certain adipokines is dependent upon the location
and effect of the energy intake of the individual.
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Major Signaling Pathways Involved in WAT Adipogenesis
The differentiation process that supports proliferation is controlled by
stimuli that can influence adipocyte growth. As mentioned, a variety of ßadrenergic factors can activate this process; however, multiple pathways can be
stimulated. The culmination of these signaling pathways represents regulators
that can promote and inhibit adipogenesis. For example, the WNT signaling
pathway has been previously described to be a strong regulator of adipocyte
differentiation. As a highly conserved signal transduction pathway that plays a
role in proliferation and differentiation during embryonic development, activation
of this pathway is essential to communicating stop-signals. In this section, other
pathways that stimulate this process and key regulators will be explored.

BMP’s
As described, MSC’s have the ability to differentiate into a variety of cell
types. The formation into pre-adipocytes can be triggered by members of the
bone morphogenic protein (BMP) family, or specifically BMP4 and BMP2. The
presence of BMP4 has been shown to commit pluripotent C2H10T1/2 cells to an
adipose lineage, confirming the development into the white adipocyte
phenotype78. Although BMP2 itself has little influence over adipogenesis, it does
interact with other factors such as TGF-ß and insulin to promote differentiation,
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although in some in vitro studies, the TGF-ß signaling cascade has also been
shown to inhibit adipogenesis by repressing C/EBP’s transcriptional activity78, 79.

MAPK’s
Mitogen activated protein kinases or MAPK’s represent a family of
signaling pathways well investigated to have the capacity to influence various cell
signaling cascades affecting adipogenesis80, 81. A subsection of this family is
comprised of extracellular signal-regulated kinases (ERKs), which function to
control cell cycle and regulation of proliferative factors. Other members of this
family include c-Jun amino-terminal kinases (JNKs) and p38 mitogen activated
kinases, which have proven to be associated with stress response and apoptotic
regulation.
In response to cytokines, osmotic stress, heat shock, fatty acids, and
growth factors, JNKs can interfere with insulin signaling pathways, promote
inflammation, induce apoptosis, and effect rates of proliferation82, 83. The direction
of the cascade events triggered by JNKs is dependent upon the specific stimuli
and cell-type associated with its activation. Although obesity and metabolic
disease research has illuminated a complex relationship between apoptotic
events and inflammation, a pathway illuminating a direct correspondence with
adipogenic factors has yet to be evidenced.
Research on p38 has proven to be even more convoluted with studies
determining a complex dynamic between activation and inhibition of proliferative
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properties. While p38 is well evidenced to be supportive of UCP1 expression in
BAT, it’s role in differentiation and glucose uptake in WAT has yielded
controversial results84. For example, considering p38 MAPK inhibitor interactions
during adipocyte differentiation, results have shown that inhibitors, such as
SB20350, during pre-adipocyte differentiation decreased the formation of
adipocytes and downregulated C/EBPß phosphorylation85. Conversely, there is
evidence that p38 may indirectly inhibit differentiation by phosphorylating
CHOP10, a member of the C/EBP family. P38 has also been shown to
phosphorylate nuclear factor of activated T-cells (NFATc4), binding with PPARγ
to inhibit its expression86. As studies examining the relationship of MAPKs with
adipogenesis continue to be explored, the development of inhibitory factors
repressing adipogenesis and modulating insulin sensitivity will remain of great
interest.

AMPK
AMPK, or AMP-activated protein kinase, is a well-known energy sensor
that is crucial to energy metabolism and regulation. Although research on AMPK
is well established, its role in adipose function is still relatively enigmatic. Various
studies have investigated how AMPK may promote adipocyte browning and
illuminate its effect on energy homeostasis. Exposure to increased AMPK levels
during adipogenesis has been shown to inhibit differentiation of WAT, and
instead, seems to induce transcription of browning factors to produce BAT or
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beige adipocytes in 3T3-L1 cells by reducing expression of PRDM1687, 88. AMPK
has been found to be indispensable to fatty acid metabolism, thermogenesis, and
development of adipose tissue. Understanding the effect of AMPK on
adipogenesis will prove to be essential to the future research explored in the
following manuscript.

3. Therapeutic Approaches
Standard Methods
Fewer topics have engendered as much controversy as the health
concerns associated with excess fat mass. Obesity was once a novel concern.
Now, obesity rates have extended across nations and populations all around the
world. A series of chronic conditions have been associated with the development
of obesity and its influence over metabolism. These conditions have been linked
to a host of other disorders that include respiratory issues and infertility. In
summation, as a large-scale analysis of over 1.4 million adults showed, obesity
was directly linked with an overall increase in mortality89.
The importance of addressing this growing epidemic with methods to
reduce instances of obesity need not be argued. Instead, efforts have
concentrated on determining and evaluating therapies for weight reduction.
Considering available methods, little more can be said for the effectiveness of
increased physical activity and monitored dietary intake. Dietary therapies come
in an innumerable number of packages, but focus primarily on decreasing dietary
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intake to create an energy deficit. Many strategies often employ the reduction of
saturated fats and carbohydrates90. This method requires patience and
consistency, as weight reduction often involves time. Obese individuals should
consider contacting nutritional specialists or seeking counsel to properly follow
dietary restrictions unique to their needs91. In order to reduce weight, an energy
deficit of 500/kcal per day is often prescribed, although certain cases may require
more extreme strategies92.
Physical activity, often in conjunction with changes in dietary intake, has
been shown to not only reduce weight, but improve other health parameters
associated with obesity93. Various forms of physical exercise are available,
including strength training, circuit training, endurance training, and high intensity
interval training94. Although each method may be found to have different levels of
energy expenditure, a mixed approach may provide the best results in combining
weight reduction and improving overall health. It is suggested that a weight
reduction of 2 kg within 6-12 months is deemed appropriate95. Though behavior
and lifestyle modifications continue to be the most effective long-term treatments
for obesity and weight reduction, dire cases have escalated the necessity for
more immediate pharmaceutical therapies. Several medications are available
through over-the-counter and prescription methods. More recognized
medications include Orlistat, a lipase inhibitor that works to prevent the
degradation of dietary triglycerides and increases their excretion96. Medications
such as this include uncomfortable adverse effects and may decrease absorption
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of fat-soluble vitamins. Phentermine is a prescription drug that decreases desire
for food, but does not influence metabolism. Similar pharmaceutical options also
work to inhibit serotonin, norepinephrine, and dopamine reuptake and influence
dietary behaviors, though long term use is not advised97.
Innovative Nutrient Strategies
For many, the adverse effects of pharmaceuticals perpetuate a sense of
unease about their safe use. Instead, a growing body of evidence suggests that a
new era of nutraceuticals may provide health specialists new means of treating
disease through the use of phytochemicals. Phytochemicals are biologically
active compounds found in plants that play a role in plant growth or defense
against pathogens, competitors, or predators98. In clinical studies,
phytochemicals have shown potential to attenuate oxidative stress and
inflammation99.
Traditional use of phytochemicals can be traced back to ancient Chinese
and Indian medicine where a variety of herbs and fruits were used to treat
ailments such as infertility, headaches, skin detoxification, and improve eyesight.
Ancient medicines also proffered therapeutic agents such as diuretics, cough
expectorants, and treatments for inflammatory disorders100. A variety of
compounds were used to treat disorders such as diabetes and cardiovascular
disease and touted hepatoprotective attributes. Current research has collected
theories from these practices to consider their health value in clinical trials;
however, results have been mixed101-103. One of the primary limitations to current
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literature is the elevated number of possible compounds investigated and the
poor means of assessing effective dosage. As an example, a PubMed search of
the term “phytochemical” alone yields over 25,000 publications with a plethora of
polyphenols making narrowing options for analysis difficult to determine. Other
topics of concern include whether researchers should isolate the most bioactive
compound or consider whole nutrient sources. Decisions among these factors
may continue to be one of the most challenging obstacles for investigators yet.

4. Zyflamend
Introduction
Zyflamend is a phytonutrient supplement that includes a variety of different
herbal extracts104. Containing the extracts from ginger, rosemary, turmeric,
Chinese goldthread, holy basil, Hu Zhang, barberry, oregano, green tea, and
Chinese skullcap, Zyflamend was originally developed based on their antiinflammatory properties. A review of associated literature has reinforced this
claim as several compounds found in Zyflamend seem to inhibit the proinflammatory pathways of MAPK’s and transcription factor nuclear factor kappalight-chain-enhancer of activated B cells (NF-kB )105, 106. Studies investigating the
beneficial potential of phytochemicals tend to focus on large doses of individual
bioactive ingredients. Alternatively, the therapeutic results of Zyflamend
interventions have been based on human-dose equivalency. Moreover, certain
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studies of Zyflamend have proposed that its robust effects may in part be due to
the synergistic capacity between ingredients104.
Currently, research efforts have asserted Zyflamend holds new relevancy
as a potent anti-cancer therapy107, 108. Although the mechanisms involved are still
being reviewed, these studies point to a potential influence over genes regulating
cell cycle and apoptosis107. NF-kB is a protein complex that is involved in
cytokine production and regulates cell survival through apoptosis inhibition109.
Previous studies have tied some of the anti-cancer effects of Zyflamend to the
regulation of NF-kB signaling pathway110. Recently, new studies have begun to
investigate how these anti-cancer pathways may interact in non-cancer cells.
There remains limited evidence on the relevancy of Zyflamend in normal cells as
its main impact with publications has been through cancer research; yet studies
have unmasked NF-kB as the primary pathway responsible for inflammation in
excess adipose tissue111. Further examination of the anti-inflammatory and
anticancer pathways effected by Zyflamend treatment suggest there may be
other connections to metabolic dysregulation. Little research has been published
on this topic, leaving many properties unexplored.
History
The first reference of Zyflamend in scientific literature came with Bemis et
al.’s publication on its nonselective cyclooxygenase-2 (COX-2) inhibition in
prostate cancer112. This research sparked a procession of studies determining
Zyflamend supplementation could induce apoptosis in prostate cancer cells.
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Several authors, several studies, several cancers, and several discoveries later
and Zyflamend research continues to yield therapeutic potential for a variety of
conditions.

A Review of the Literature
A review of the scientific literature on Zyflamend emphasizes a focus on
its therapeutic properties in cancer. Even so, general mechanistic studies have
revealed various effects on anti-inflammatory pathways. Several studies have
suggested that Zyflamend may attenuate inflammation through multiple signaling
pathways107, 113, 114. Some studies concluded Zyflamend may suppress COX 1/2
activity, although many studies emphasized inhibition of NF-kB as the major
pathway of interest, specifically through its primary transcription factor Re1A107,
113, 115

. Suppression of NF-kB resulted in reduction of TNF-alpha and other pro-

inflammatory mediators and improvement of pro-apoptotic events.
Other studies on Zyflamend’s effect on metabolomics expressed its ability
to modify cellular energetics. Zyflamend has been shown to activate AMPK in
vivo116. The mechanisms of AMPK activation suggest an ability to regulate
specific pathways promoting lipolysis and promoting adipose tissue reduction
through tumor suppressor liver kinase B-1 (LKB1)104. These preliminary studies
suggest potential in utilizing Zyflamend in metabolic research. However,
understanding the true mechanism involved may provide researchers with the
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insight necessary to determine how effective Zyflamend may be as a potential
therapy.

Components
The ingredients of Zyflamend include ginger, rosemary, turmeric, Chinese
goldthread, holy basil, Hu Zhang, barberry, oregano, green tea, and Chinese
skullcap. Many of these herbs are touted for their various anti-diabetic, anticancer, and anti-oxidant benefits. Of the ingredients, several have been shown to
exhibit anti-inflammatory properties as well. Health specialists have deemed
obesity a chronic low-grade inflammatory disease13. Research has suggested
that results of phytochemical supplementation may contribute to decreased
inflammation attributed to metabolic diseases; however, the translatability to
clinical trials has much to be desired. This review explores the shift towards
holistic therapeutic approaches to find increased effectiveness when treating
metabolic disease. Furthermore, this field is shifting from novel basic science
research towards real clinical application as the development of phytochemical
therapies continues to show promise.
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5. Research Objectives
Specific Aims
Obesity is a continued global health concern that directly correlates with
significant health consequences. Prevalence of obesity has been associated with
a multitude of metabolic disorders like type 2 diabetes mellitus, dyslipidemia,
cardiovascular disease, hypertension, as well as other physiological disorders
and injuries like liver dysfunction, cancer, and respiratory disorders. These
comorbidities are exacerbated by the pro-inflammatory nature of the disease,
thus, determining potential new therapeutic approaches to decrease adipose
tissue is vital for more effectively treating obesity.
Found in a variety of fruits, vegetables, and spices, phytochemicals are
naturally occurring compounds commonly consumed. These therapeutic
phytochemicals also use a variety of pathways ranging from increasing the
efficacy of certain enzymes’ antioxidant activity, posttranslational modification of
key signaling molecules, and regulation of gene expression4. Zyflamend, an
herbal supplement has been used standardly as a medicinal anti-inflammatory
agent. Previous studies have tied the anti-cancer effects of Zyflamend to the
regulation of the NF-kB signaling pathway and phosphorylation of AMPK
suggesting that Zyflamend may influence metabolic factors that could provide
therapeutic treatment to combat obesity. However, certain questions remain
unanswered: (1) what is the effect of Zyflamend on non-cancer cells, such as
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white adipocytes, and (2) what molecular mechanisms mediate the effectiveness
of Zyflamend and its influence over adipogenesis?
The central hypothesis of this study is that Zyflamend supplementation
attenuates adipogenesis; however, its mechanisms will be determined.

Specific Aim 1: To determine the effects of Zyflamend in vitro on adipocyte
differentiation using molecular techniques. We will use the well-established
model that employs 3T3-L1 cells. Through innovative methods, we expect to
explore the interactions that occur with a translatable human dose of Zyflamend
treatment.
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CHAPTER TWO
THE CROSS-TALK BETWEEN PKA AND JNK MEDIATES THE
ANTI-ADIPOGENIC POTENTIAL OF ZYFLAMEND, A UNIQUE
HERBAL BLEND
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ABSTRACT
Zyflamend, a polyphenol herbal supplement, includes numerous different
extracts. This botanical complex has been used as an anti-inflammatory due to its
impact on the NF-kB signaling pathway. However, recent research has exhibited
its potential as an anti-cancer agent by stimulating AMPK and shifting the
metabolic dynamic in cancer cells. Currently, the effects of Zyflamend in noncancer cells has yet to be elucidated. This study sought to explore the interactions
of Zyflamend treatment on non-cancer cells such as 3T3-L1 adipocytes. The
results of this study showed that Zyflamend significantly attenuated adipogenesis.
As evidenced in previous research, Zyflamend was found to increase
phosphorylation of AMPK and downregulate markers of lipogenesis, decreasing
glucose uptake and upregulating lipolytic enzymes. It was determined this pathway
occurred by upregulation of PKA-regulated lipolysis through pHSLS660. In
addition, Zyflamend drastically increased activity of MAPK activity, specifically
JNK. Through investigation of these effects, partial rescue of adipogenesis was
observed through treatments with PKA inhibitor H89 and AMPK inhibitor BML275;
however JNK inhibitor SP600125 more significantly rescued the effects of
Zyflamend on differentiation. These results suggest Zyflamend’s effect on
attenuating adipogenesis may be modulated by upregulation of JNK.
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SIGNIFICANCE
Zyflamend has been shown to downregulate NF-kB and upregulate AMPK
activity in cancer cells, resulting in a shift in metabolism that results in cancer cell
death. AMPK activity is also an essential part of metabolism and can impact the
differentiation of non-cancer cells. Currently, methods to promote activation of
AMPK have been used in metabolic research to influence the differentiation of
adipocytes, primary energy storage cells. By addressing the mechanisms
associated with adipocyte differentiation, adipogenesis has become a target for a
variety of therapeutic approaches in metabolic research. Zyflamend’s ability to
shift energy metabolism and promote energy expenditure may yield therapeutic
potential as a cell differentiation modulator.
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1. Introduction
Obesity is a global health concern that directly correlates with significant
health consequences. Obesity is caused by excessive energy consumption and
can lead to an increased mortality rate through a variety of comorbidities making
therapeutic and preventative approaches to these conditions of top interest to
health professionals118. Type 2 diabetes mellitus, dyslipidemia, cardiovascular
disease, hypertension, as well as other physiological disorders, like liver
dysfunction, musculoskeletal and respiratory disorders, and cancer, all have
shown a close correlation with BMI and prevalence of increased body weight119.
These comorbidities are exacerbated by the pro-inflammatory nature of the
disease related to a dynamic immune response in adipocytes120. Customary
ways to decrease the accumulation of adipose tissue are effective through longterm efforts; however, finding inventive methods to attenuate adipose tissue may
be instrumental to improving health prognosis for extreme cases.
Directed efforts to understand the intricate changes in adipocyte
morphology may hold the key to treating adipocyte dysfunction associated with
obesity121. Various transcription factors have been identified that promote the
differentiation of white adipocytes from adipocyte precursors. Peroxisome
proliferator-activated receptor gamma (PPAR-γ) initiates lipid uptake and drives
differentiation of adipocytes. In addition, sterol regulatory element-binding
transcription factor 1 (SREBF1) promotes glucose metabolism and supports fatty
acid and lipid production within the cell122, 123. These factors, and others
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associated with energy storage and metabolism, promote the maturation
necessary for fully differentiated adipocytes. Once mature, these cells act as
energy storage sites and modulate hormone signaling to a variety of tissues.
Targeting adipogenesis has been on the forefront of obesity research, making
downregulation of transcription factors that drive this process a natural mark for
study124.
In clinical studies, certain phytochemicals have been found to induce a
catabolic state by activating energy sensor adenosine monophosphate-activated
protein kinase (AMPK) promoting fatty acid oxidation and even adipocyte
“browning” 125,126. Many phytochemicals have been shown to express antiinflammatory, antioxidative, anticancer, and anti-obesity affects127. Thorough
investigation into a multitude of these compounds have yielded promising results
to counter a variety of ailments, including pomegranate flavonoids, sulforaphane,
turmeric, and quercetin. Each therapeutic phytochemical can vary in its
mechanistic pathway or target ranging from increasing the efficiency of certain
enzymes’ antioxidant activity, activating or preventing PPAR-γ and the
inflammatory NF-kB pathway, to upregulating gene expressions associated with
autophagy128.
As mentioned, research investigating the effects of phytochemicals on
adipose tissue development often illustrate changes in metabolism through
AMPK. AMPK is a key regulator in cellular metabolism, known to heighten
energy production and attenuate energy storage processes129. AMPK’s role in
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energy homeostasis is well evidenced through its stimulation of lipolytic
mechanisms and its ability to improve insulin sensitivity130. Additionally, cyclic
AMP-dependent protein kinase A (PKA) is a multifunctional protein that can
initiate lipolytic events by phosphorylating hormone-sensitive lipases (HSL)130.
Phosphorylated HSL translocates from the cytosol to stored triglycerides in the
reservoir lipid droplet in adipocytes and exhibits an increase in hydrolytic
activity131. Both PKA and AMPK have been shown to stimulate these hydrolytic
events by HSL through different serine residues132. Upregulation of this pathway
can inhibit normal differentiation processes associated with adipose tissue
maturation. Several studies have confirmed fatty acid oxidation and mobilization
can effectively halt adipogenesis when AMPK and HSL activity is promoted133.
Zyflamend has shown efficacy in regulating inflammation and metabolism
in cancer cells; perhaps in part due to the synergy expressed by its
ingredients133-137. Although these mechanisms are not well understood, studies
point to potential influence over genes regulating the cell cycle, autophagy, and
apoptosis138. Furthermore, they have identified AMPK as responsible in shifting
the metabolic dynamic in cancer cells, promoting apoptosis. As AMPK activity
can support changes in metabolism through upregulation lipolysis, we wished to
investigate how Zyflamend may activate this pathway in non-cancer cells, such
as in adipocytes139.
In this study, we examined the anti-adipogenic potential of Zyflamend and
the underlying mechanisms involved. The results showed that Zyflamend
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significantly decreased adipocyte differentiation in vitro by upregulating lipolysis
activity and suppressing the activity of differentiation transcription factors PPAR-y
and lipogenic enzymes fatty acid synthase and perilipin A. Additionally,
upregulation of lipolytic mechanisms were noted. Furthermore, these processes
were shown to be mediated by upregulation of JNK and increased activity of
PKA-mediated HSL activity.

2. Materials and Methods
Chemicals and Reagents. Media, sera and trypsin for cell culture were
purchased from Gibco (Thermo Fisher Scientific, Waltham, MA). Zyflamend was
purchased from New Chapter Inc. (Brattleboro, VT). Primary antibodies and
secondary antibodies were acquired from varying sources (Table 1). Chemical
reagents such as dithiothreitol (DTT), percoll, digitonin, phenylmethylsulfonyl
fluoride (PMSF), protease inhibitors cocktail, sodium deoxycholate, Triton X-100,
ethylene glycol-bis-(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), sodium
fluoride (NaF), Sodium phenylbutyrate (4-PBA), Hoechst 33258, propidium
iodide, autophagy inhibitor (DBeQ), JNK inhibitor (SP600125), Thapsigargin,
AICAR, TUDCA, HS38, H89, SB203580, STK1, Fasudil, and KT572 were
acquired from Millipore-Sigma (Burlington, MA). Finally, AMPK inhibitor
(BML275) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA)
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Cell Culture. Brown precursor cells were isolated from newborn wild type mouse
by collagenase digestion as described previously, from brown fat pads140. 3T3-L1
MBX (ATCC ® CRL-3242) cells were maintained in DMEM containing 25 mM
glucose, 10% FBS, 50 U/ml penicillin and 50 μg/ml streptomycin. To induce cell
differentiation, white, brown and 3T3-MBX pre-adipocytes were grown to
confluence in culture medium containing 10% FBS. Confluent cells were then
switched to differentiation media containing 10% FBS, 20 nM insulin and 1 nM
triiodothyronine [T3] for 48 hours. Adipocyte differentiation was induced by
treating cells for 48 h in differentiation medium further supplemented with 5 µM
dexamethasone, 0.5 mM isobutylmethylxanthine, and 0.125 mM indomethacin
(induction media). After induction, cells were returned to differentiation medium
and exhibited a fully differentiated phenotype with accumulation of fat droplets.

Zyflamend Treatment. Zyflamend was dissolved in DMSO at a concentration of
800mg/ml for the stock solution. Cells were treated with Zyflamend at the
indicated concentration and for the indicated duration. Treatment was stopped by
two washes with ice-cold phosphate buffer saline (PBS). Plates were then flash
frozen in liquid nitrogen and stored at -80ºC until further analyses.

Cytotoxicity Assay. Cytotoxicity assays were performed using sulforhodamine
B (Millipore-Sigma) as previously described141. Briefly, 3T3-MBX pre-adipocytes
were treated with Zyflamend at 37°C in an atmosphere of 10% CO2 for the
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indicated time. After the incubation, the cells were fixed with 17% trichloroacetic
acid in PBS and cellular protein was stained for 10 min at room temperature with
0.4% sulforhodamine B in 1% acetic acid solution. The plates were washed with
water and dried, and the stain was dissolved in 0.2 mL 10 mM Tris (pH 9).
Quantification of sulforhodamine B was carried out using the Synergy™ HTX
Multi-Mode microplate reader (BioTek Instruments, Inc. Winooski, VT) at a
wavelength of 540 nm. The relative plating efficiency of each cell line was
determined by dividing the absorbance observed for a given treatment by the
absorbance detected in the absence of treatment and expressed as a fold
change.

Quantification of Lipid Accumulation and Oil Red O Staining. On Day 12 of
differentiation, cells were fixed with 10% PBS buffered formalin for at least 12
hour at 4°C. Cells were stained for one hour with filtered oil red O solution (5 g/L
in isopropyl alcohol), washed with distilled water, and examined using the Leica
DMI8 inverted microscope (Leica Microsystems Inc. Buffalo Grove, IL).

Western Blotting Analysis. Cells were lysed in radio-immunoprecipitation assay
(RIPARIPA: 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% sodium dodecyl
sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5 mM EDTA, 1 mM
NaF, 1 mM sodium orthovanadate and protease inhibitors) as we previously
described142. Lysates were clarified by centrifugation at 15,000 g for 10 min, and
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protein concentrations were determined using a bicinchoninic acid assay kit
(Thermo Scientific Pierce BCA Protein Assay). Proteins (10-30 μg) were resolved
by SDS-PAGE and transferred to PVDF membranes. Immunoblotting of lysates
was performed with primary antibodies (Table 1), and after incubation with
secondary antibodies, proteins were visualized using Luminata™ Western
Chemiluminescent HRP Substrate (Millipore). Pixel intensities of immunoreactive
bands were quantified using FluorChem Q Imaging software (Alpha Innotech
Corp, San Leandro, CA). Data for phosphorylated proteins are presented as
phosphorylation normalized to protein expression while total protein expression
was normalized to β-actin as loading control.

RNA Extraction, RT-PCR And Real-Time PCR. RNA was extracted from cells
using TRIzol reagent (Invitrogen). The concentration of RNAs was determined
using the NanoDrop® ND-1000 spectrophotometer (Thermo Scientific). Specific
DNA products were generated with an RT-PCR system (high-capacity cDNA
Synthesis Kit (Applied Biosystems). Primer sets are described in Table 2 and
expression of different genes was assessed by quantitative real-time PCR using
SsoAdvanced™ Universal SYBR® Green Supermix (BioRad) and the Bio-Rad
CFX96™ system. Relative abundance of target gene mRNA was measured
using the ∆∆CT method and normalized to Tata-box binding protein (Tbp) as
previously described.
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Annexin V Staining. Annexin V staining was performed as previously described
with modification143. Briefly, 3T3-MBX pre-adipocytes were exposed to
Zyflamend [for the indicated duration] then washed with PBS and resuspended in
0.5ml of binding buffer (10 mM HEPES/NaOH, pH 7.5, 140 mM NaCl, and
2.5 mM CaCl2) containing 5 μl of fluorescein isothiocyanate (FITC)-conjugated
Annexin V (BD Pharmingen, San Diego, CA) and 10 μl of propidium iodide (PI)
(Millipore-Sigma, Burlington, MA) for 10 min at room temperature in the dark.
Cells (5,000) were then analyzed using the Guava® easyCyte Flow Cytometer
(Millipore-Sigma). Intensities of fluorescence emitted by Annexin V-FITC
(530 nm) and PI (585 nm) were collected on FL1 and FL3 channels, respectively.
Both viable (negative for Annexin V and PI staining) and apoptotic cells (positive
for Annexin V, but negative for PI staining) were quantified using CellQuest
software (BD Biosciences, San Jose, CA).

Cell Cycle Analysis. Cell cycle analysis was determined by examining the DNA
content of cells stained with propidium iodide as previously described with
modification144. Briefly, 3T3-MBX pre-adipocytes were exposed to Zyflamend [for
the indicated duration] then washed with PBS and fixed in 70% ethanol for
12hours at 4°C. After, cells were washed twice with cold PBS and then incubated
in RNase solution in PBS (100 U/ml) for 30 min at 37°C. Cells were then
incubated in solution of propidium iodide solution (10 μg/ml in PBS) overnight at
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4°C. Fluorescence was measured using the Guava® easyCyte flow cytometer
and analyzed with ModFitLTTM cell cycle analysis program (Becton Dickinson).

2-Deoxyglucose Uptake Assay. 2-Deoxyglucose uptake was determined using
the colorimetric glucose uptake assay kit (Biovison INC., Milpitas, CA). Briefly,
differentiated 3T3-MBX adipocytes were starved in low glucose (1mM) and 0%
FBS media then treated with insulin for 30 minutes in the presence of 2deoxyglucose. Cells were then washed with ice-cold PBS and the accumulated
2-Deoxyglucose was quantitated using the Synergy™ HTX Multi-Mode
microplate reader.

Statistical Analysis. Data are expressed as means +/- standard error of the
mean (SEM). All statistical analyses were performed with JMP program (SAS
Institute, NC) using an unpaired heteroscedastic two-tail Student's t test.
Differences were considered significant at p<0.05 and highly significant at
p<0.01. Single symbol (such as *) corresponds to p<0.05, while double (such as
**) corresponds to p<0.01.

3. Results
In this study, we sought to investigate the effects of Zyflamend on lipid
accumulation and differentiation of white adipocytes. 3T3-MBX white preadipocytes were treated with increased concentrations of Zyflamend and
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differentiation into fully mature white adipocytes was carried as described in the
methods and outlined in Fig. 1B-C. On Day 12 of differentiation, cells were stained
using the fat-specific dye Oil Red O to monitor lipid accumulation (Fig. 1C-E) To
rule out off-target effects, control cells (0 ug/ml) were treated with the highest
concentration of the vehicle DMSO (1.25 ul/ml). On day 12 of differentiation, these
cells accumulated fat droplets and exhibited a fully differentiated phenotype with
more than 85% of the cells containing fat droplets (Fig. 1D). In contrast, cells
treated with Zyflamend resulted in a dose-dependent decrease in lipid
accumulation and only a small percentage of cells (<10%) were able to accumulate
fat.

Notably, cells treated with 1 mg/ml of Zyflamend exhibited blunted

differentiation on Day 12 and were comparable to the non-differentiated cells at
Day 1 of differentiation.
To determine whether Zyflamend would alter adipogenesis of 3T3-MBX at
this dose, we examined changes in lipid accumulation over a time course
experiment over 12 days of differentiation. Consistent with the previous
experiment, this dose significantly attenuated adipogenesis as judged by Oil red O
staining and lipid accumulation (Fig. 2A-B).
A growing body of literature indicates that Zyflamend exhibits anti-survival
and pro-apoptotic effects on several cancer models135, 145-146. However, its effects
on non-cancer cells have yet to be investigated. To address this, we examined
the effects of Zyflamend on pre-adipocyte proliferation using the sulforhodamine B
cytotoxicity assay. Zyflamend inhibited differentiation of 3T3-MBX pre-adipocytes
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in the presence of Zyflamend (200ug/ml) compared to DMSO (0.25ul/ml) as a
vehicle control as shown in (Fig. 2C),
We demonstrate that the expression of cyclins D1 and D2, which repress
adipocyte differentiation, were significantly attenuated in Zyflamend treated cells
in comparison to the control. The exception was D3, which did not show significant
differences in response to Zyflamend.
Expanding on these findings, we examined alterations in cell cycle and cell
death in response to Zyflamend treatment. To examine whether attenuation of
adipogenesis is caused by changes in cell proliferation, we also examined cell
death of 3T3-MBX pre-adipocytes. These cells were cultured in the presence of
Zyflamend (200ug/ml) or DMSO (0.25ul/ml) as a vehicle control for up to 48 hours.
Cells treated with Zyflamend exhibited blunted proliferation. The intensity of the
SRB staining reflected significant variation in the cell proliferation rate from a 12hour time point to 48 hours (p<0.05) between treated and non-treated cells.
Patterns of differentiation correlate with expression of adipogenic
markers: To further investigate the effects of Zyflamend on white adipose
differentiation, we determined the expression of adipogenic markers fatty acid
synthase (Fas), pyruvate carboxylase (PCB), perilipin, peroxisome proliferatoractivated receptor gamma (PPARγ), CCAAT-enhancer binding protein alpha
(c/EBPα), adiponectin, and glucose transporter 4 (Glut 4). Consistent with previous
report, FAS, PCB, c/EBP adiponectin, PPARγ exhibited a progressive increase in
expression during differentiation in control cells treated with the vehicle DMSO
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(Fig. 3A)147. Conversely, cells treated with Zyflamend at a dose of 200 ug/ml
exhibited blunted expression of these proteins throughout differentiation. In
addition, we examined changes in other proteins associated with the nondifferentiated state of white adipocytes such as pre-adipocyte factor 1 (Pref1), α5
integrin, fibronectin, and suppressor of cytokine signaling 9 (Sox9). The expression
pattern of Pref1, α5 integrin, fibronectin, and Sox9 were comparable during the
differentiation of control cells and exhibited a blunted expression by day 12 of
differentiation. Cells treated with Zyflamend, on the other hand, maintained high
levels of these proteins throughout differentiation. Consistent with protein
expression, pref1 RNA was higher in Zyflamend treated cells compared to controls
(Fig 3.B). Next, the expression of several white fat specific genes was determined
during differentiation of control and Zyflamend-treated cells. Consistent with the
protein data, control cells exhibited a marked increase of mRNA in fas, ap2,
resistin, c/ebp1a, and adiponectin. Zyflamend treatment abolished the expression
of these genes. Additionally, changes in glucose uptake were also noted, with
Zyflamend treatment modulating insulin response (Fig. 4). Taken together our data
suggest that cells treated with Zyflamend exhibited attenuated differentiation, as
indicated by lipid accumulation and changes in protein and mRNA expression.
Zyflamend induces lipolysis in fully differentiated 3T3-MBX
adipocytes: To investigate the molecular basis for the attenuated adipogenesis
and decreased lipogenesis in Zyflamend-treated cells, we assessed the levels of
adipogenesis and lipolysis markers in these cells. Zyflamend induces the
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phosphorylation and activation of AMPK in a dose dependent manner. The
increased AMPK phosphorylation and its activation were associated with a
significant increase in ACC phosphorylation at Ser9, inhibiting its activity (Fig.
5A-B). CPT1a expression was also reduced in Zyflamend treated-cells (Fig. 5AB).
To examine whether the reduction in fatty acid synthesis was associated
with increased lipolysis, we evaluated changes in energy storage markers. We
conducted a dose response of Zyflamend and examined changes in protein
expression of hormone-sensitive lipase (HSL) (Fig. 5C). As Zyflamend
concentration increased, pHSL expression increased at serine sites 563, 565,
and 660. PKA-mediated phosphorylation of HSL at S563 and S660 is essential
for HSL translocation to lipid droplets and triacylglycerol hydrolysis148-149. During
a time course experiment over 12 days, alterations in pHSL activity were noted
between Zyflamend and DMSO. In the control, pHSL at S563 showed an
increased and then proceeding decrease of activity, whereas Zyflamend
treatment showed little phosphorylation until Day 12. Over the time course,
phosphorylation of pHSL at S565, which is dependent on AMPK, was shown to
decreased during normal differentiation activity with the DMSO control.
Conversely, it remains at low activity during Zyflamend treatment.
Phosphorylated HSL at S660 is shown to remain at low expression during the
control treatment, but is significantly upregulated with Zyflamend treatment (Fig.
5D). Consistent with these findings, PKA activity was significantly higher during
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differentiation of Zyflamend-treated cells compared to controls as judged by the
phosphorylation of PKA substrates (Fig. 5G). Collectively, this data indicates
that the Zyflamend-induced lipolysis in 3T3-MBX is PKA dependent by
upregulation of pHSL by S660.
To determine if browning was a factor in changes of metabolic activity, we
assessed the expression of the brown adipose marker UCP1. UCP1 protein was
expressed in brown adipocytes (positive control) after 12 days of differentiation
but not in Zyflamend-treated cells. Similarly, the expression of PRDM16 and
BMP7 were highly expressed in brown adipocytes but not in white adipocytes
treated with Zyflamend, confirming that Zyflamend treatment, while altering
lipolysis and energy metabolism, does not induce browning of white 3T3-MBX
adipocytes (Fig. 5I).
We examined activation of MAP kinases during the course of
differentiation of 3T3-MBX cells. Zyflamend exhibited a marked increase in JNK
phosphorylation, particularly on Day 6 (Fig. 6A). Consistent with the activation of
JNK, Zyflamend also increased the phosphorylation and activation of the JNK
canonical downstream effectors, namely c-Fos and c-Jun. To further prove this
hypothesis, we treated differentiating 3T3-MBX cells with Zyflamend along with
specific inhibitors of PKA, p38 and JNK. We also used BML275 as a specific
inhibitor for AMPK. As shown in Fig. 7, inhibition of JNK or PKA with SP600125
and H89, respectively, reversed the effects of Zyflamend on differentiation as
judged by lipid accumulation Oil Red O staining (Fig. 7A-C). Inhibition of p38
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using SB203580 did not rescue the effects of Zyflamend on differentiation (data
not shown). Inhibition of AMPK on the other hand, resulted in a moderate rescue
of Zyflamend-induced attenuation of lipid accumulation in 3T3-MBX cells (Fig.
7A-B). Together these data suggest that the impaired differentiation by
Zyflamend is mainly mediated through the activation of PKA and JNK signaling
pathways.
The cross-talk between PKA and JNK mediates the anti-adipogenic
potential of Zyflamend: Despite the large body of evidence implicating both
PKA and JNK in stimulating lipolysis during adipocytes differentiation, little is
known about the crosstalk between these two proteins in coordinating the
hydrolysis of triglycerides and how this affects the overall differentiation process.
To address this question, we used PKA and JNK inhibitors and examined
changes in differentiation and triglyceride content (Fig. 7A). We also evaluated
the effects of inhibiting both proteins on the overall differentiation process by
examining changes in the expression of the differentiation markers; Fas, PCB,
Perilipin, and Pref1 (Fig 7B). Our study indicates that inhibition of PKA markedly
attenuated the phosphorylation and activation of JNK while rescuing the effects
of Zyflamend on the differentiation markers. On the other hand, while inhibition of
JNK restored the expression of the differentiation markers in Zyflamend-treated
cells, Zyflamend-induced PKA activation appears to decline (Fig. 7C-D). These
results suggest that JNK is downstream target the PKA signaling and that our
study demonstrates that Zyflamend attenuates differentiation of 3T3-MBX
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adipocyte through the activation of PKA, which in turns activates JNK. Finally,
future studies are necessary to further determine the underlying mechanisms of
JNK activation by PKA, such as examining the molecular mechanisms mediating
the cross-talk between PKA and JNK.

4. Discussion
Zyflamend’s proven ability to activate AMPK and downregulate the NF-kB
inflammatory pathway has identified it as a potent moderator for cancer. However,
this study’s intent was to identify how Zyflamend treatment using an evidenced
human dose equivalent may influence metabolism in non-cancer cells and
determine its impact on cell metabolism.
This study is the first of its kind to explore a direct relationship in Zyflamend
treatment and metabolic research. We sought to investigate the effect of
Zyflamend on adipocyte differentiation and determine the potential mechanisms
involved. We discovered that Zyflamend significantly attenuated adipogenesis in
3T3-MBX adipocytes by inhibiting lipid storage and upregulating lipolysis. We
propose that these affects are due to Zyflamend’s ability to increase PKA and JNK
signaling pathways. Considering these effects, we determine Zyflamend may have
strong, natural therapeutic potential to address the development of adipose tissue,
novel to metabolic research.
The differentiation process of adipocytes relies heavily on cell signaling
pathways that identify and respond to anabolic stimuli. As adipose tissue is a key
regulator and storage site of energy intake, the development of adipose tissue
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bears great responsibility in managing growth, energy accessibility, and other
metabolic processes. The ability for pre-adipocytes to fully differentiate and
mediate energy storage in the form of triglycerides is essential for the development
of obesity. Previous cancer research has established the efficacy of the human
dose equivalent 200 ug/ml as an effective modulator in cancer studies. As this
study is novel in design, our initial focus was to verify its efficacy in normal cells.
First and foremost, we determined that 200 ug/ml was sufficient to promote
changes in adipocytes differentiation. We noted attenuation of differentiation of
3T3-MBX cells as judged by the abolished lipid accumulation, and decreased
expression of differentiation markers. Due to changes in lipid metabolism, we also
sought to verify Zyflamend’s ability to activate AMPK and determine this effect’s
contribution to the shift in energy metabolism. Our observations support previous
research, suggesting Zyflamend can effectively activate AMPK and decrease the
activity of growth and survival pathways through AKT.
Certain ingredients of Zyflamend previously studied exhibit the potential to
activate AMPK and mediate adipogenesis. To name a few ginger, turmeric, and
green tea have been shown to disrupt the onset of obesity, noting their ability to
inhibit adipose expansion and suppress differentiation via activation of AMPK
through food derived components150. Similar studies have noted the impact of
Turmeric on activation of lipolysis through adipose triglyceride lipase and hormone
sensitive lipase151. This activity can stunt the process of differentiation by
decreasing the cell’s ability to develop the lipid droplet and suppress anabolic
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mechanisms that promote growth. The ability for the ingredients of Zyflamend to
mobilize stored triglycerides supports our findings without the necessity of doses
such 500g/kg body weight as evidenced in previous literature151. As discussed,
Zyflamend exhibits unique synergistic affects improving the efficacy of the
ingredients’ biological reactions at relatively low quantity of the components
promoting the translatability of our study. Furthermore, Zyflamend increased the
activity of HSL at S660, suggesting PKA may be mediating lipolysis activity.
We were able to determine the effects of Zyflamend increasing lipolytic
mechanisms in white pre-adipocytes were not due to the upregulation and
expression of a brown phenotype. We determined that Zyflamend inhibited UCP1
expression, suggesting that the metabolic shift was independent of browning
mechanisms. Currently, investigations to increase rates of brown or beige
adipocytes has led the forefront of obesity research. The thermogenic potential of
this phenotype has supported many research efforts to increase natural energy
expenditure. As this area of research continues to grow, we propose exploring
other biological avenues of obesity interventions. Previous research investigating
the metabolomic potential of Zyflamend has previously reported attenuation of
adipose tissue in C57BL/6 mice treated with Zyflamend204. However, this study did
not differentiate the prevalence of brown adipose tissue, suggesting our findings
are supportive of the potential of Zyflamend treatment through an alternative
strategy.
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We sought to determine how AMPK, JNK, and PKA activation induced by
Zyflamend influenced the process of differentiation. Using specific inhibitors of
each, we observed that inhibition of these key regulators impacted the overall
effects of Zyflamend on the differentiation process. However, inhibition of JNK
through SP600125 was able to rescue the effects of Zyflamend most significantly
and promote normal adipogenesis. This outcome suggests it is Zyflamend’s ability
to activate JNK that prevents maturation of 3T3-BMX pre-adipocytes.
This treatment attenuated adipogenesis and significantly decreased the
uptake and storage of glucose and lipids. Some studies have published similar
effects on adipogenesis through some of the components of Zyflamend. Previous
research determined the effects of curcumin as suppressing differentiation by
promoting apoptosis of 3T3-L1 adipocytes151. In our investigations, the compound
Zyflamend was able to suppress these effects without significantly altering cell
proliferation rates.
We observed increased activity of HSL at S660. As we described, HSL as
S660 is activated not through AMPK, but through upstream activator PKA. This
has yielded rare insight into the complex interactions occurring from Zyflamend
treatment. Other studies have yet to observe this interaction between PKA activity.
When exploring how PKA inhibitor H89 influenced the reaction of Zyflamend
treatment during adipogenesis, we observed a stronger rescue reaction from
inhibition of PKA in comparison to AMPK inhibitor BML275. This suggests that
there may be more mechanisms at play than what has been previously published.
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We aimed to determine the key regulator attenuating the adipogenesis we
observed in 3T3-MBX pre-adipocytes treated with Zyflamend. We determined that
JNK activity was particularly upregulated in these cells. Although the mechanisms
that promote this activation have yet to be explored, our study evidenced JNK has
having a potent lipolytic role. By exploring how JNK inhibitor SP600125 interacted
with the effects of Zyflamend, we observed a rescue effect suggesting JNK
activation is essential for Zyflamend’s effect on abolishing lipid storage and
differentiation. There is reference to the lipolytic action of JNK in various studies;
although we have yet to determine what mechanisms may be driving this force,
previous literature hypothesizes autophagy and ER stress.
This study provides novel insight into the potential of phytochemical
interventions in metabolic disease. Despite this study being novel within the current
literature, future studies are warranted to investigate the relationship between JNK
activation and the differentiation process of adipocytes. The transition towards
abandoning conventional pharmaceutical methods and embracing holistic and
synergistic bioactive nutrient therapies presents a transformative paradigm to
disease research. This study was designed to incorporate a shift in perspective
utilizing nutrition basic science research to establish a counterargument to more
traditional therapeutic approaches. Zyflamend has already established itself in
previous cancer research to provide therapeutic potential when more traditional
strategies are exhausted. In this study, we demonstrated the plausibility of future
Zyflamend research toward addressing metabolic diseases. Further analysis of the
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mechanisms at play are required before solidifying Zyflamend’s role in obesity
interventions, however the potential remains.
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CHAPTER THREE
CONCLUSION AND FUTURE PERSPECTIVES
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1. Conclusion
Recent studies have demonstrated that Zyflamend triggers a dosedependent anti-lipogenic response in prostate cancer cells through the activation
of the energy sensor AMP-activated protein kinase (AMPK)131,

133, 138, 147

. The

findings from this study suggest that Zyflamend-induced PKA activation may alter
lipid metabolism in adipocytes and dysregulate adipocyte differentiation. Adipocyte
differentiation is a complex process that requires integration of a multitude of
stimuli including nutrients and hormones and is often marked by the increased
expression of several genes involved in adipogenesis and lipid accumulation27. In
this study, we sought to investigate the effects of Zyflamend on lipid accumulation
and differentiation of white adipocytes. Several factors may explain the decreased
differentiation of Zyflamend-treated cells such as increased cell death, elevated
lipolysis, reduced lipogenesis, loss of contact inhibition, inhibition of clonal
expansion, transdifferentiation into brown-like adipocytes, etc. Thus, we conducted
a detailed analysis of the effects of Zyflamend on pre-adipocyte proliferation, cell
cycle, cell death, and differentiation. Together with our findings on PKA, these
results suggest that PKA and/or JNK signaling pathways are what potentially
mediate the effects of Zyflamend on adipocytes differentiation.
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2. Future Perspectives
As Zyflamend has been shown across the literature to be a modulator of
inflammation and regulator of metabolism in cancer cells, future research should
continue to investigate and explore the effects of Zyflamend treatments against
non-cancer cells. This study explored the potential of Zyflamend to regulate
normal metabolic function within adipocytes and provided evidence of its
potential as a modulator of adipocyte differentiation. These methods will help to
elucidate the mechanisms that regulate this process through upregulation of JNK
and PKA-mediated lipolysis. However, the necessity to further determine the
complex mechanisms at work may show its potential in metabolic studies.
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Table S1: List of primers used to quantitate the mRNA levels of markers of
differentiation
Gene
18s

Forward 5’->3’
GCAATTATTCCCCATGAAC
G
Adiponect TGTTCCTCTTAATCCTGCCC
in
A
Ap2
GCTTTGCCACAAGGAAAGT
G
Cebp1
GGTCAACAGGAGAATCTCC
CAG
Fas
AGAGATCCCGAGACGCTTC
T
Pref1
CCCAGGTGAGCTTCGAGTG
Resistin

CTGTCCAGTCTATCCTTGC
ACAC
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Reverse 5'->3'
GGCCTCACTAAACCATCCAA
CCAACCTGCACAAGTTCCCTT
CATAACACATTCCACCACCA
CTCTGTTTTATGCTGTTATGG
GTGA
GCCTGGTAGGCATTCTGTAGT
GGAGAGGGGTACTCTTGTTG
AG
CAGAAGGCACAGCAGTCTTG
A

Table S1: List of primary antibodies and conditions of use.

Table S2: List of primary antibodies and conditions of use.
Antibodies
ACC
Adiponectin
AMPK
BMP7
C/EBP
c-Fos
c-Jun
CPT1a
Cyclin D1
Cyclin D2
Cyclin D3
Fas
Fibronectin
Glut4
HSL
JNK1/2
MnSOD
p38
PCB
Perilipin

Source
Cell Signaling
Technology
Abcam
Cell Signaling
Technology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Abcam
Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Cell Signaling
Technology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
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Host

Dilution

Rabbit

1:2,000

Rabbit

1: 1,000

Rabbit

1:5,000

Mouse

1:1,000

Mouse

1:1,000

Mouse

1:1,000

Mouse

1:1,000

Mouse

1: 1,000

Rabbit

1:5,000

Rabbit

1:2,500

Rabbit

1:5,000

Mouse

1:5,000

Mouse

1: 1,000

Mouse

1:5,000

Rabbit

1:1,000

Mouse

1:1,000

Mouse

1:2,500

Mouse

1:1,000

Mouse

1:5,000

Mouse

1:1,000

Table S2 Continued
Antibodies
Phospho-ACCS9
Phospho-AMPKT172
Phospho-c-JunS63
Phospho-HSLS563
Phospho-HSLS565
Phospho-HSLS660
Phospho-JNK1/2T183/Y185
Phospho-p38T180/Y182
Phospho-PKA Substrate
(RRXS*/T*)
PPARγ
PRDM16
Pref 1
Sox9
UCP1
α5 Integrin
β-Actin

Source
Cell Signaling
Technology
Cell Signaling
Technology
Santa Cruz
Biotechnology
Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Cell Signaling
Technology
Cell Signaling
Technology
Abcam
Cell Signaling
Technology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
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Host

Dilution

Rabbit

1:1,000

Rabbit

1:2,500

Mouse

1:1,000

Rabbit

1:1,000

Rabbit

1:1,000

Rabbit

1:1,000

Mouse

1:1,000

Mouse

1:1,000

Rabbit

1:5,000

Rabbit

1:1,000

Mouse

1: 2,000

Rabbit

1:1,000

Mouse

1:1,000

Mouse

1:5,000

Mouse

1: 1,000

Mouse

1:20,000

Figure 1. Dose Dependent Effect of Zyflamend on adipocytes
differentiation. A) Composition of Zyflamend. B) A Schematic illustration of the
differentiation procedure. C) 3T3-MBX were differentiated in the presence of
increasing doses of Zyflamend for 12 days. Cells were fixed and stained with oil
red O. C) Oil red O-stained and (D) phase contrast mages of non-differentiated
(day 1) and differentiated adipocytes (day 12). Scale bar: 200 μm Images on the
right panel are magnification of the boxed regions. D) Oil Red O stain was
extracted and its absorbance (520 nm) was quantitated. Graph represents data
from six independent experiments, and data are expressed as mean + SEM.
*p<0.05, **p<0.01 indicate significant difference between non-treated and
Zyflamend treated cells. E.) Dose Dependent Effect of Zyflamend on adipocytes
Zyflamend treated cells and triglyceride content.
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Figure 2. A physiologically relevant dose of Zyflamend inhibits adipocytes
differentiation and glucose uptake. A) 3T3-MBX pre-adipocytes were treated
with DMSO or 200 ug/ml of Zyflamend and differentiated as described in the
Methods section. At different days of differentiation, cells were fixed and stained
with oil Red O, and then triglyceride content was quantitated
spectrophotometrically (520 nm) quantitated (B). Graph represents data from six
independent experiments, and data are expressed as mean + SEM. *p<0.05,
**p<0.01 indicate significant difference between the indicated time and day one
of differentiation. †p<0.05, ††p<0.01 indicate significant difference between
Zyflamend and control (DMSO) treated cells. C) 3T3-MBX pre-adipocytes were
treated with DMSO or 200 ug/ml of Zyflamend for the indicated time and cell
survival was assessed using the sulfide-reducing bacteria (SRB) cytotoxicity
assay as detailed in the Methods section. Bar graphs represent the intensity of
SRB staining reflective of the cell number and presented as means + SEM.
*p<0.05, **p<0.01 indicate significant difference between cell proliferation rate at
the indicated time point and 12hours. †p<0.05, ††p<0.01 indicate significant
difference between non-treated and Zyflamend treated cells (50 ug/ml–500
ug/ml). D) Assessment of DNA content and cell cycle analysis in 3T3-MBX preadipocytes treated with DMSO or Zyflamend. Representative histogram
distributions for each treatment are shown. E) Bar graphs represent the
percentages of cells in each phase of the cell cycle which were estimated using
the GuavaSuite Software package and are presented as means +/- SEM from
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three independent experiments. *p<0.05, **p<0.01 indicate significant difference
the indicated concentration and control cells treated with the vehicle DMSO. F)
Immunoblots of cell cycle regulators cyclins D1, D2, and D3 in cells treated with
200 ug/ml of Zyflamend at various stages of differentiation. Representative
Immunoblots from three independent experiments are shown. G) Bar graphs
represent Cyclin D1, D2 and D3 normalized to β-Actin as a loading control and
presented as means + SEM. *p<0.05, **p<0.01 indicate significant difference the
indicated time point and day 1 of differentiation. †p<0.05, ††p<0.01 indicate
significant difference between Zyflamend and control (DMSO treated) cells. H-I)
50% confluent cells were treated with increasing concentrations of Zyflamend (50
ug/ml–500 ug/ml), and then labelled with Annexin V-FITC and 7-AAD.
Representative dot plots are shown. Annexin V positive and /7-AAD negative
cells (lower right quadrants) represent early stages of apoptosis, whereas cells
that are positive for both Annexin V and 7-AAD (upper right quadrants) are in late
stage of apoptosis. Bar graphs represent live, early, and late apoptotic cells are
presented as means +/- SEM of at least three independent experiments. *p<0.05,
**p<0.01 indicate significant difference the indicated concentration and control
cells treated with the vehicle DMSO.

78

79

Figure 3. Zyflamend inhibits differentiation of 3T3-MBX pre-adipocytes. A)
Immunoblots of adipogenic markers in 3T3-MBX cells treated or non-treated with
Zyflamend (200ug/ml) at varying stages of differentiation. Lysates were blotted
for β-actin to control for loading. Representative Immunoblots from three
independent experiments are shown. B) Bar graphs represent the indicated
protein normalized to β-Actin as means + SEM. *p<0.05, **p<0.01 indicate
significant difference between indicated time points and day 1 for each cell type.
†p<0.05, ††p<0.01 indicate significant difference between Zyflamend and control
(DMSO) treated cells. C) Quantitative (q) RT-PCR of Fas, Pref1, Resistin, Ap2,
Adiponectin, Cebp1a, Pparg, Perilipin, Sreb1c, Fadb4, Visfatin, and Cidea mRNA
levels in control and Zyflamend (200 ug/ml) treated cells at various days of
differentiation. Data are normalized to 18S ribosomal RNA (18S rRNA). Results
are representative of three independent experiments and data are expressed as
mean +/- SEM. *p<0.05, **p<0.01 indicate significant difference between
indicated time points and day 1 for each treatment. †p<0.05, ††p<0.01 indicate
significant difference between Zyflamend and control (DMSO) treated cells.
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Figure 1: Zyflamend inhibits differentiation of 3T3-MBX pre-adipocytes.
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Figure 4. Zyflamend inhibits glucose uptake. 3T3-MBX pre-adipocytes were
treated with DMSO or 200 ug/ml of Zyflamend and differentiated as described in
the methods section. On day 12, cells were starved overnight in low glucose (1
mM) and 0% FBS media then treated with insulin for 30 minutes in the presence
of 2-deoxyglucose. 2-doxyglucose uptake was quantified and presented as
means +/- SEM of three independent experiments. Graph represents data from
four independent experiments, and data are expressed as mean +/- SEM.
*p<0.05, **p<0.01 indicate significant difference between the insulin treated and
non-treated cells. †p<0.05, ††p<0.01 indicate significant difference between
Zyflamend and control (DMSO) treated cells.
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Figure 5. Zyflamend inhibits lipogenesis and induces lipolysis in fully
differentiated 3T3-MBX adipocytes. Total lysates from fully differentiated 3T3MBX adipocytes treated with the indicated concentrations of Zyflamend (0-400
ug/ml) for 24 hrs were immunoblotted for markers of lipogenesis (A-B) and
lipolysis (C-D). Representative Immunoblots from three independent experiments
are shown. B-D) Bar graphs represent pAMPKT172/AMPK, Fas/β-Actin,
pACCS79/ACC, CPT1α/β-Actin, pAKTS473/AKT, pGSKS9/GSK, pHSLS563/HSL,
pHSLS565/HSL, pHSLS660/HSL, and HSL/ β-Actin as means + SEM. *p<0.05,
**p<0.01 indicate significant difference between indicated concentration of
Zyflamend and control (0) untreated cells. E-F) Immunoblots of pHSLS563,
pHSLS565, pHSLS660, and HSL in 3T3-MBX cells treated or non-treated with
Zyflamend (200 ug/ml) at varying stages of differentiation. Representative
Immunoblots from three independent experiments are shown. F) Bar graphs
represent pHSLS563/HSL, pHSLS565/HSL, pHSLS660/HSL, and HSL/ β-Actin as
means + SEM. *p<0.05, **p<0.01 indicate significant difference between
indicated time points and day 1 for each treatment. †p<0.05, ††p<0.01 indicate
significant difference between Zyflamend and control (DMSO) treated cells. G-H)
Immunoblots of phosphorylated PKA substrate in 3T3-MBX cells treated or nontreated with Zyflamend (200ug/ml) at varying stages of differentiation.
Representative Immunoblots from three independent experiments are shown. H)
Bar graphs represent phosphorylated PKA substrate /β-Actin as means + SEM.
*p<0.05, **p<0.01 indicate significant difference between indicated time points
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and day 1 for each treatment. †p<0.05, ††p<0.01 indicate significant difference
between Zyflamend and control (DMSO) treated cells. I) Immunoblots of UCP1,
prdm16, and BMP7 in 3T3-MBX cells treated or non-treated with Zyflamend
(200ug/ml) at varying stages of differentiation. Primary inguinal fully differentiated
brown adipocytes (BAT) were used as positive control.
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Figure 5 continued
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Figure 6. Zyflamend activates JNK and PKA during the differentiation of
3T3-MBX adipocytes. Total cell lysates from control and Zyflamend treated
cells at various stages of differentiation were immunoblotted for (A)
phosphorylated p38, JNK, c-Jun and their respective unphosphorylated proteins,
c-Fos. Samples were also blotted for β-Actin as a loading control. Representative
immunoblots from three independent experiments are shown. B) Bar graphs
represent pp38T180/Y182/p38, pJNKT183/Y185/JNK, pc-JunS63/c-Jun, and c-Fos/βActin as means + SEM. p<0.05, **p<0.01 indicate significant difference between
indicated time points and day 1 for each treatment. †p<0.05, ††p<0.01 indicate
significant difference between Zyflamend and control (DMSO) treated cells.
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Figure 7. Inhibition of PKA and JNK abrogates the effects of Zyflamend on
differentiation A) Oil red O-stained images of non-differentiated (day 1) and
differentiated adipocytes (day 12) treated or non-treated with AMPK (BML-275),
JNK (SP600125) or PKA (H89) inhibitors. B) Oil Red O stain was extracted and
its absorbance (520 nm) was quantitated. Graph represents data from at least
six independent experiments, and data are expressed as mean +/- SEM.
*p<0.05, **p<0.01 indicate significant difference between non-treated and
Zyflamend treated cells. †p<0.05, ††p<0.01 indicate significant difference
between cells treated with the indicated inhibitor together with Zyflamend and
cells treated with Zyflamend only. C) Phase contrast images of non-differentiated
(day 1/D1) and differentiated adipocytes (day 12/D12) treated or non-treated with
SP600125 or H89. Images in the right panel are magnification of the boxed
regions. Scale bar: 200 μm. D-G) Immunoblots of adipogenic markers in 3T3MBX cells treated or non-treated with Zyflamend (200ug/ml) with or without PKA
inhibitor (H89; D) or JNK inhibitor (SP600125; F). Lysates were blotted for β-actin
to control for loading. Representative Immunoblots from three independent
experiments are shown. E-G) Bar graphs represent the indicated protein
normalized to β-Actin as means +/- SEM. *p<0.05, **p<0.01 indicate significant
difference between day 12 and day 1 of differentiation for each treatment.
†p<0.05, ††p<0.01 indicate significant difference between inhibitor-treated and
non-treated cells.

88

Figure 2: Inhibition of PKA and JNK abrogates the effects of Zyflamend on
differentiation
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Figure 7 continued
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